Financial assistance
Financial assistance
AVEO ACE Co-pay Assistance Program*
Patients who have commercial or private insurance may be eligible to enroll in the AVEO ACE Co-pay Assistance Program. If approved, your patient could pay as little as $0 for their FOTIVDA. Annual limits of $25,000 apply.
Eligibility requirements
A patient must:
- Be a resident of the US or US Territory
- Have a commercial (private) insurance plan
- Not be enrolled in any government-funded insurance programs (Medicare, Medicaid, etc)
AVEO ACE Patient Assistance Program
Patients who are uninsured or underinsured may access FOTIVDA free of charge through the AVEO ACE Patient Assistance Program.
Eligibility requirements
The FOTIVDA® (tivozanib) Co-pay Card program provides eligible, commercially insured patients up to $25,000 per calendar year toward a patient’s FOTIVDA prescription costs. The FOTIVDA Co-pay Card program is not valid for uninsured patients. Annual and transaction limits apply. No other purchase is necessary.
Eligible patients must be prescribed FOTIVDA for an FDA-approved indication.
Eligible patients with a FOTIVDA prescription may pay as little as $0 toward their out-of-pocket costs. Patients must be 18 years or older to enroll and activate a co-pay card. The program can only be used by eligible residents of the United States, Puerto Rico, and Guam, and at participating pharmacies.
The offer does not constitute prescription drug coverage and is not intended to substitute for health insurance. The offer is not available to patients receiving any form of prescription coverage under any federal, state, or government-funded insurance program or where prohibited by law. Such programs include Medicare (including Medicare Part D and Medicare Advantage), Medicaid, TRICARE, Department of Defense, and Veterans Affairs programs. If at any time a patient begins receiving prescription drug coverage under any federal, state, or government-funded healthcare program, the patient will no longer be able to use the FOTIVDA Co-pay Card and the patient must call AVEO ACE patient support at 1-833-368-4832 to terminate participation.
Read More +How to Apply
To determine if your patient may be eligible for the AVEO ACE Patient Assistance Program, you and your patient must:
Enroll online
OR
Download and print
the AVEO ACE enrollment form
and fax the completed form
to 1-888-920-2830.
AVEO ACE will evaluate the patient for eligibility and communicate the results to you and your patient within 24 hours.
DISCLAIMER:
AVEO ACE makes no representation or guarantee concerning reimbursement or coverage for any service or item. Information provided through the AVEO ACE program does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed healthcare professional, legal counsel, or applicable third-party payer(s). AVEO ACE reserves the right to modify the program at any time without notice.
View available ongoing education and support.
Explore comprehensive insurance coverage support resources.
INDICATIONS
FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Hypertension was reported in 45% of patients (22% ≥ Grade 3). Hypertensive crises were reported in 0.8% of patients. Do not initiate FOTIVDA in patients with uncontrolled hypertension. Monitor for hypertension and treat as needed. Reduce the FOTIVDA dose for persistent hypertension not controlled by anti-hypertensive medications. Discontinue FOTIVDA for severe hypertension that cannot be controlled with anti-hypertensive therapy or for hypertensive crisis.
INDICATIONS
FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Hypertension was reported in 45% of patients (22% ≥ Grade 3). Hypertensive crises were reported in 0.8% of patients. Do not initiate FOTIVDA in patients with uncontrolled hypertension. Monitor for hypertension and treat as needed. Reduce the FOTIVDA dose for persistent hypertension not controlled by anti-hypertensive medications. Discontinue FOTIVDA for severe hypertension that cannot be controlled with anti-hypertensive therapy or for hypertensive crisis.
Cardiac failures were reported in 1.6% of patients (1% ≥ Grade 3); 0.6% of events were fatal. Monitor for signs or symptoms of cardiac failure during treatment with FOTIVDA. Manage with dose interruption, dose reduction, or discontinuation.
Cardiac ischemia were reported in 3.2% of patients; 0.4% of events were fatal. Arterial thromboembolic events were reported in 2.0% of patients, including death due to ischemic stroke (0.1%). Closely monitor patients at risk for, or who have a history of these events. Discontinue FOTIVDA in patients who develop severe arterial thromboembolic events, such as myocardial infarction and stroke.
Venous Thrombotic Events (VTE) were reported in 2.4% of patients, including 0.3% fatal events. Closely monitor patients who are at increased risk for these events. Discontinue in patients who develop serious VTEs.
Hemorrhagic Events were reported in 11% of patients; 0.2% of events were fatal. Use FOTIVDA with caution in patients who are at risk for or who have a history of bleeding.
Proteinuria was reported in 8% of patients (2% = Grade 3). Monitor during treatment with FOTIVDA. For moderate to severe proteinuria, reduce the dose or interrupt treatment. Discontinue in patients who develop nephrotic syndrome.
Gastrointestinal (GI) Perforation including fatal cases, has been reported in patients receiving FOTIVDA. Monitor for symptoms of GI perforation or fistula formation periodically throughout treatment with FOTIVDA. Permanently discontinue FOTIVDA in patients who develop severe or life-threatening GI perforation.
Thyroid Dysfunction events were reported in 11% of patients (0.3% ≥ Grade 3). Monitor thyroid function before and during treatment with FOTIVDA.
Wound Healing Complications: Withhold FOTIVDA for at least 24 days prior to elective surgery and do not administer for at least 2 weeks after major surgery and until adequate wound healing is observed.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS) can occur with FOTIVDA. Evaluate for RPLS in patients presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue if signs or symptoms of RPLS occur.
Embryo-fetal Toxicity: FOTIVDA can cause fetal harm. Advise patients of the potential risk to a fetus, to avoid becoming pregnant and to use contraception during treatment and for one month after the last dose of FOTIVDA. Advise males with female partners of reproductive potential to use effective contraception during treatment and for one month after the last dose of FOTIVDA.
Allergic Reaction to Tartrazine: FOTIVDA 0.89 mg capsule contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible patients.
ADVERSE REACTIONS
Common adverse reactions include fatigue/asthenia, hypertension, diarrhea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, and stomatitis.
Serious adverse reactions include bleeding (3.5%), venous thromboembolism (3.5%), arterial thromboembolism (2.9%), acute kidney injury (2.3%), and hepatobiliary disorders (2.3%).
DRUG INTERACTIONS
Avoid coadministration with strong CYP3A4 inducers.
USE IN SPECIFIC POPULATIONS
Advise women not to breastfeed during treatment and for at least 1 month after the last dose.
The recommended dosage for patients with end-stage renal disease has not been established.
Reduce the FOTIVDA dose for patients with moderate hepatic impairment. The recommended dosage in patients with severe hepatic impairment has not been established.
To report SUSPECTED ADVERSE REACTIONS, contact AVEO Pharmaceuticals, Inc. at 1-833-FOTIVDA (1-833-368-4832) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information for FOTIVDA® (tivozanib).
